Analysts are bullish on Sarepta's future, predicting full U....

Analysts are bullish on Sarepta's future, predicting full U.S. approval. Strong demand for the therapy among eligible patients is also anticipated. The FDA is unlikely to withdraw the drug's accelerated approval and may expand Elevidys's label.